Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

Clynes, Raphael A., Towers, Terri L., Presta, Leonard G., Ravetch, Jeffrey V.·2000·Nature Medicine

DOI 10.1038/74704

Cited by (1,007)

Items 401–500 of 1,007

The role of Fc gamma receptors in the activity of immunomodulatory antibodies for cancer
Ross A. Stewart, Scott A. Hammond, Michael D. Oberst, Robert W. Wilkinson · 2014 · Journal for ImmunoTherapy of Cancer
Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy
Juan Carlos Almagro, Tracy R. Daniels‐Wells, Sonia Mayra Pérez‐Tapia, Manuel L. Penichet · 2018 · Frontiers in Immunology
Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo.
Camelia Spiridon, Maria-Ana Ghetie, Jonathan W. Uhr, Radu Marcheş, Jia Ling Li, Guo Liang Shen, Ellen S. Vitetta · 2002 · PubMed
Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer
Márk Barok, Minna Tanner, Katri Köninki, Jorma J Isola · 2011 · Cancer Letters
Near-infrared Theranostic Photoimmunotherapy (PIT): Repeated Exposure of Light Enhances the Effect of Immunoconjugate
Makoto Mitsunaga, Takahito Nakajima, Kohei Sano, Peter L. Choyke, Hisataka Kobayashi · 2012 · Bioconjugate Chemistry
Priming agents transiently reduce the clearance of cell-free DNA to improve liquid biopsies
Carmen Martin-Alonso, Shervin Tabrizi, Kan Xiong, Timothy Blewett, Sainetra Sridhar, Andjela Crnjac, Sahil Patel, Zhenyi An, Ahmet Bekdemir, Douglas Shea et al. · 2024 · Science
Targeting co-stimulatory pathways: transplantation and autoimmunity
Mandy L. Ford, Andrew B. Adams, Thomas C. Pearson · 2013 · Nature Reviews Nephrology
Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells
Victor Gall, Anne V. Philips, Na Qiao, Karen Clise-Dwyer, Alexander A. Perakis, Mao Zhang, Guy Travis Clifton, Pariya Sukhumalchandra, Qing Ma, Sangeetha Meda Reddy et al. · 2017 · Cancer Research
IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages
Meili Zhang, Bernard Wen, Olga M. Antón, Zhengsheng Yao, Sigrid P. Dubois, Wei Ju, Noriko Sato, David J. DiLillo, Richard N. Bamford, Jeffrey V. Ravetch et al. · 2018 · Proceedings of the National Academy of Sciences
Highly efficient deletion of FUT8 in CHO cell lines using zinc‐finger nucleases yields cells that produce completely nonfucosylated antibodies
Malphettes, Laetitia, Freyvert, Yevgeniy, Chang, Jennifer, Liu, Pei‐Qi, Chan, Edmond, Miller, Jeffrey C., Zhou, Zhe, Nguyen, Thu, Tsai, Christina, Snowden, Andrew W. et al. · 2010 · Biotechnology and Bioengineering
Vγ9Vδ2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs—Rituximab and trastuzumab
Hirotake Tokuyama, Tomomi Hagi, Stephen R. Mattarollo, Jacqueline S. Morley, Qiao Wang, Hang-Fai So, Fuminori Moriyasu, Mie Nieda, Andrew J. Nicol · 2008 · International Journal of Cancer
Correlation between NK function and response to trastuzumab in metastatic breast cancer patients
Alessandra Beano, Elena Signorino, Andrea Evangelista, Davide Brusa, Marinella Mistrangelo, Maria Antonia Polimeni, Rosella Spadi, Michela Donadio, Libero Ciuffreda, Lina Matera · 2008 · Journal of Translational Medicine
Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12
Anne Krug, Andreas Towarowski, Stefanie Britsch, Simon Rothenfußer, Veit Hornung, Robert Bals, Thomas Giese, Hartmut Engelmann, Stefan Endres, Arthur Μ. Krieg et al. · 2001 · European Journal of Immunology
Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways.
Stephan Mathas, Anke Rickers, Kurt Bommert, Bernd Dörken, Markus Y. Mapara · 2000 · PubMed
The role of Fc–FcγR interactions in IgG-mediated microbial neutralization
Stylianos Bournazos, David J. DiLillo, Jeffrey V. Ravetch · 2015 · The Journal of Experimental Medicine
PlGF Blockade Does Not Inhibit Angiogenesis during Primary Tumor Growth
Carlos Bais, Xiumin Wu, Jenny J. Yao, Suya Yang, Yongping Crawford, Krista M. McCutcheon, Christine Tan, Ganesh A. Kolumam, Jean-Michel Vernes, Jeffrey Eastham‐Anderson et al. · 2010 · Cell
The HER family and cancer: emerging molecular mechanisms and therapeutic targets
Natalia V. Sergina, Mark M. Moasser · 2007 · Trends in Molecular Medicine
The Therapeutic Landscape of Rheumatoid Arthritis: Current State and Future Directions
Shahin Shams, Joseph M. Martinez, John R.D. Dawson, J. Casado Flores, Marina Gabriel, Gustavo Garcia, Amanda Ladrón de Guevara, Kaitlin M. Murray, Noah J. Pacifici, Maxemiliano V. Vargas et al. · 2021 · Frontiers in Pharmacology
Tumour exosomes inhibit binding of tumour-reactive antibodies to tumour cells and reduce ADCC
Christina Battke, Romana Ruiss, Ulrich N. WELSCH, Pauline Wimberger, Stephan Lang, Simon Jochum, Reinhard Zeidler · 2011 · Cancer Immunology Immunotherapy
Overview of Antibody Drug Delivery
Sahar Awwad, Ukrit Angkawinitwong · 2018 · Pharmaceutics
Neutrophils mediate antibody-induced antitumor effects in mice
Marcello Albanesi, David A. Mancardi, Friederike Jönsson, Bruno Iannascoli, Laurence Fiette, James P. Di Santo, Clifford A. Lowell, Pierre Bruhns · 2013 · Blood
Blockade of CD112R and TIGIT signaling sensitizes human natural killer cell functions
Feng Xu, Alexander Sunderland, Yue Zhou, Richard David Schulick, Barish H. Edil, Yuwen Zhu · 2017 · Cancer Immunology Immunotherapy
Immature Neutrophils Mediate Tumor Cell Killing via IgA but Not IgG Fc Receptors
Marielle A. Otten, Esther Rudolph, Michael Dechant, Cornelis W. Tuk, Rogier M. Reijmers, Robert H.J. Beelen, Jan G. J. van de Winkel, Marjolein van Egmond · 2005 · The Journal of Immunology
Anti-Vascular Endothelial Growth Factor Receptor-1 Antagonist Antibody as a Therapeutic Agent for Cancer
Yan Ling Wu, Zhaojing Zhong, James Huber, Rajiv Bassi, Bridget Finnerty, Erik Corcoran, Huiling Li, Elizabeth C. Navarro, Paul J. Balderes, Xenia Jimenez et al. · 2006 · Clinical Cancer Research
Variation in gene expression patterns in follicular lymphoma and the response to rituximab
Sean P. Bohen, Olga G. Troyanskaya, Orly Alter, Roger A. Warnke, David Botstein, Patrick O. Brown, Ronald Levy · 2003 · Proceedings of the National Academy of Sciences
Antibody-Recruiting Molecules: An Emerging Paradigm for Engaging Immune Function in Treating Human Disease
Patrick J. McEnaney, Christopher G. Parker, Andrew X. Zhang, David A. Spiegel · 2012 · ACS Chemical Biology
Current approaches and future directions in the treatment of HER2-positive breast cancer
Sara Alsterlind Hurvitz, Yufang Hu, Neil A. O’Brien, Richard S. Finn · 2012 · Cancer Treatment Reviews
Dual Mode of Action of a Human Anti-Epidermal Growth Factor Receptor Monoclonal Antibody for Cancer Therapy
Wim K. Bleeker, Jeroen J. Lammerts van Bueren, Heidi H. van Ojik, Arnout F. Gerritsen, Marielle Pluyter, Mischa Houtkamp, Ed Halk, Joel Goldstein, Janine Schuurman, Marc A. van Dijk et al. · 2004 · The Journal of Immunology
Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-α/β–inducible gene expression, without significant toxicity
Jonathan W. Friedberg, Helen Kim, Mary McCauley, Edith M. Hessel, Paul W. Sims, David Christopher Fisher, Lee Marshall Nadler, Robert L. Coffman, Arnold S. Freedman · 2004 · Blood
The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
R. Todd Reilly, Jean-Pascal Machiels, Leisha A. Emens, Anne M. Ercolini, Francesca I. Okoye, R.Y. Lei, D Weintraub, Elizabeth M. Jaffee · 2001 · PubMed
In vivoTargeting of Human Neutralizing Antibodies against CD55 and CD59 to Lymphoma Cells Increases the Antitumor Activity of Rituximab
Paolo Macor, Claudio Tripodo, Sonia Zorzet, Erich Piovan, Fleur Bossi, Roberto Marzari, Alberto Amadori, Francesco Tedesco · 2007 · Cancer Research
Capecitabine and Trastuzumab in Heavily Pretreated Metastatic Breast Cancer
Rupert Bartsch, Catharina Wenzel, Gabriela Altorjai, Ursula Pluschnig, Margaretha Rudas, Robert M. Mader, Michael Gnant, Christoph Carl Zielinski, Guenther G. Steger · 2007 · Journal of Clinical Oncology
Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct
Anja Löffler, Michael Gruen, Christian Wuchter, Folke Schriever, Peter Kufer, Torsten Dreier, Frank Hanakam, Patrick A. Baeuerle, Kurt Bommert, Leonid Karawajew et al. · 2003 · Leukemia
Developments and Challenges for mAb-Based Therapeutics
Goswami, Sumit, Wang, Wei, Arakawa, Tsutomu, Ohtake, Satoshi · 2013 · Antibodies
Rituximab Pharmacokinetics in Patients With Rheumatoid Arthritis: B‐Cell Levels Do Not Correlate With Clinical Response
佳子白川, Sunil Agarwal, Ming Yin, Song Ren, Nicole F. Li, Tim M. Shaw, Brian E. Davies · 2007 · The Journal of Clinical Pharmacology
Thrice-Weekly Low-Dose Rituximab Decreases CD20 Loss via Shaving and Promotes Enhanced Targeting in Chronic Lymphocytic Leukemia
Michael E. Williams, John J. Densmore, Andrew W. Pawluczkowycz, Paul V. Beum, Adam D. Kennedy, Margaret A. Lindorfer, Susan Hamil, Jane C. Eggleton, Ronald P. Taylor · 2006 · The Journal of Immunology
Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies
Julie Gertner-Dardenne, Cécile Bonnafous, Christine Bezombes, Aude-Hélène Capietto, Virginie Scaglione, Sophie Ingoure, Delphine Cendron, Emilie T. E. Gross, Jean-François Lepage, Anne Quillet‐Mary et al. · 2009 · Blood
The insulin and EGF receptor structures: new insights into ligand-induced receptor activation
Colin Wesley Ward, Michael C. Lawrence, Victor A. Streltsov, Timothy E. Adams, Neil M. McKern · 2007 · Trends in Biochemical Sciences
Fcγ receptor pathways during active and passive immunization
Stylianos Bournazos, Jeffrey V. Ravetch · 2015 · Immunological Reviews
Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo
Liang N. Zhang, Zhengzi Qian, Zhen Cai, Luhong Sun, Huaqing Wang, J. Blake Bartlett, Qing Yi, Michael L. Wang · 2009 · American Journal of Hematology
Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer
Sherene Loi, Stefan Michiels, Diether Lambrechts, Debora Fumagalli, Bart Claes, Pirkko‐Liisa Kellokumpu‐Lehtinen, Petri Bono, Vesa V Kataja, Martine J Piccart, Heikki Joensuu et al. · 2013 · JNCI Journal of the National Cancer Institute
Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer
Zsuzsanna Pályi‐Krekk, Márk Barok, Jorma J Isola, Markku Tammi, János Szöllo ̋si, Péter Nagy · 2007 · European Journal of Cancer
Antibody-Mediated Blockade of Integrin αvβ6 Inhibits Tumor Progression In vivo by a Transforming Growth Factor-β–Regulated Mechanism
Koopman Van Aarsen, Louise A., Leone, Diane R., Ho, Steffan, Dolinski, Brian M., McCoon, Patricia E., LePage, Doreen J., Kelly, Rebecca, Heaney, Glenna, Rayhorn, Paul, Reid, Carl et al. · 2008 · Cancer Research
The Activation of Natural Killer Cell Effector Functions by Cetuximab-Coated, Epidermal Growth Factor Receptor–Positive Tumor Cells is Enhanced By Cytokines
Julie M. Roda, Trupti Joshi, Jonathan P. Butchar, Jaclyn W. McAlees, Amy Lehman, Susheela Tridandapani, William Edgar Carson · 2007 · Clinical Cancer Research
Cancer cells educate natural killer cells to a metastasis-promoting cell state
Isaac S. Chan, Hildur Knútsdóttir, Gayathri Ramakrishnan, Veena Padmanaban, Manisha Warrier, Juan Carlos Ramı́rez, Matthew Dunworth, Hao Zhang, Elizabeth M. Jaffee, Joel S. Bader et al. · 2020 · The Journal of Cell Biology
Structural and functional characterization of the trifunctional antibody catumaxomab
Dirk Chelius, Peter Ruf, Patrick Gruber, Matthias Plöscher, Reinhard Liedtke, Eva Gansberger, Juergen Heß, Michael Wasiliu, Horst Lindhofer · 2010 · mAbs
Induction of Cytosolic Calcium Flux by CD20 Is Dependent upon B Cell Antigen Receptor Signaling
Claire A. Walshe, Stephen A. Beers, Ruth R. French, H.T. Claude Chan, Peter Johnson, Graham Packham, Martin J. Glennie, Mark Steven Cragg · 2008 · Journal of Biological Chemistry
Rational bases for the development of EGFR inhibitors for cancer treatment
Roberto Bianco, Teresa Gelardi, Vincenzo Damiano, Fortunato Ciardiello, Giampaolo Tortora · 2007 · The International Journal of Biochemistry & Cell Biology
Strategies for Delaying or TreatingIn vivoAcquired Resistance to Trastuzumab in Human Breast Cancer Xenografts
Jeanne M. du Manoir, Giulio Francia, Shan Man, Miriam E. Mossoba, Jeffrey A. Medin, Alicia Viloria‐Petit, Daniel J. Hicklin, Urban Emmenegger, Robert S. Kerbel · 2006 · Clinical Cancer Research
Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines
Denis Martin Collins, Norma O’Donovan, Patricia M. McGowan, Finbarr O’Sullivan, Michael Joe Duffy, John Paul Crown · 2011 · Annals of Oncology
Tumor-Associated Hyaluronan Limits Efficacy of Monoclonal Antibody Therapy
Netai C. Singha, Tara Nekoroski, Chun‐Mei Zhao, Rebecca C. Symons, Ping Jiang, Gregory I. Frost, Zhongdong Huang, Harold Michael Shepard · 2014 · Molecular Cancer Therapeutics
Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy
Ido Amit, Ron Wides, Yosef Yarden · 2007 · Molecular Systems Biology
Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines
Nadja S. Prang, Susanne Preithner, Klaus Brischwein, P Göster, A Wöppel, J Müller, Carola Steiger, Matthew J. Peters, Patrick A. Baeuerle, A J da Silva · 2005 · British Journal of Cancer
Oncogenic growth factor receptors: implications for signal transduction therapy
Yaron Mosesson, Yosef Yarden · 2004 · Seminars in Cancer Biology
Intratumoral Delivery of IL-21 Overcomes Anti-Her2/Neu Resistance through Shifting Tumor-Associated Macrophages from M2 to M1 Phenotype
Meng Michelle Xu, Mingyue Liu, Xuexiang Du, Sirui Li, Hang Li, Xiaozhu Li, Ying Li, Yang Wang, Zhihai Qin, Yang‐Xin Fu et al. · 2015 · The Journal of Immunology
Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses
Andres G. Grandea, Ole Olsen, Thomas C. Cox, Mark W. Renshaw, Philip W. Hammond, Po-Ying Chan-Hui, Jennifer L. Mitcham, Witold Cieplak, Shaun M. Stewart, Michael L. Grantham et al. · 2010 · Proceedings of the National Academy of Sciences
Mechanisms of resistance to HER family targeting antibodies
Tim J. Kruser, Deric L. Wheeler · 2010 · Experimental Cell Research
CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells
Julie A. Bowles, George J. Weiner · 2005 · Journal of Immunological Methods
Boosting therapeutic potency of antibodies by taming Fc domain functions
Tae Hyun Kang, Sang Taek Jung · 2019 · Experimental & Molecular Medicine
An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab
Adam D. Kennedy, Michael D. Solga, Theodore A. Schuman, Amos W. Chi, Margaret A. Lindorfer, William M. Sutherland, Patricia L. Foley, Ronald P. Taylor · 2003 · Blood
Antitumor Efficacy of a Combination of CMC-544 (Inotuzumab Ozogamicin), a CD22-Targeted Cytotoxic Immunoconjugate of Calicheamicin, and Rituximab against Non-Hodgkin's B-Cell Lymphoma
John F. DiJoseph, Maureen M. Dougher, Lyka B. Kalyandrug, Douglas C. Armellino, Erwin R. Boghaert, Philip R. Hamann, Justin K. Moran, Nitin K. Damle · 2006 · Clinical Cancer Research
Overexpression of endocan induces tumor formation.
Arnaud Scherpereel, Thibaut Gentina, Bogdan Dragoş Grigoriu, Stéphanie Sénéchal, Anne Janin, Anne Tsicopoulos, François Plénat, David Béchard, André‐Bernard Tonnel, Philippe Lassalle · 2003 · PubMed
Drifts in ADCC-related quality attributes of Herceptin®: Impact on development of a trastuzumab biosimilar
Seokkyun Kim, Jinsu Song, Seungkyu Park, Sunyoung Ham, Kyungyeol Paek, Min‐Jung Kang, Yunjung Chae, Heewon Seo, Hyung-Chan Kim, Michael Flores · 2017 · mAbs
Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non‐Hodgkin's lymphoma
Jonathan W. Friedberg, Donna S Neuberg, John G. Gribben, David Christopher Fisher, Christine M. Canning, Margaret A. Koval, Christine M. Poor, Luke M. Green, John F. Daley, Robert J. Soiffer et al. · 2002 · British Journal of Haematology
Immune-mediated mechanisms influencing the efficacy of anticancer therapies
Seth B. Coffelt, Karin E. de Visser · 2015 · Trends in Immunology
Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical
Zhao Xiaobin, Rosa Lapalombella, Trupti Joshi, Carolyn M. Cheney, Aruna C. Gowda, Martha S. Hayden-Ledbetter, Peter R. Baum, Thomas S. Lin, David G. Jarjoura, Amy Lehman et al. · 2007 · Blood
Nanoparticle Targeting of Neutrophils for Improved Cancer Immunotherapy
Dafeng Chu, Qi Zhao, Jian Yu, Faya Zhang, Hui Zhang, Zhenjia Wang · 2016 · Advanced Healthcare Materials
Silencing of the HER2/neu Gene by siRNA Inhibits Proliferation and Induces Apoptosis in HER2/neu-Overexpressing Breast Cancer Cells
Timo Faltus, Juping Yuan, Brigitte Zimmer, Andrea Krämer, Sibylle Loibl, Manfred Kaufmann, Klaus Strebhardt · 2004 · Neoplasia
Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study
T. Igarashi, Yukio Kobayashi, Michinori Ogura, T. Kinoshita, T. Ohtsu, Yosuke Sasaki, Yoshiyuki MORISHIMA, Takashi Murate, M Kasai, Naokuni Uike et al. · 2002 · Annals of Oncology
Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model
Siao‐Yi Wang, Suresh Veeramani, Emilian V. Racila, Jeffrey R. Cagley, David C. Fritzinger, Carl-Wilhelm Vogel, William St. John, George J. Weiner · 2009 · Blood
Improving Treatment of HER2-Positive Cancers: Opportunities and Challenges
Howard Marvin Stern · 2012 · Science Translational Medicine
The Evolving Landscape of HER2 Targeting in Breast Cancer
Mark M. Moasser, Ian E. Krop · 2015 · JAMA Oncology
The role and function of Fcγ receptors on myeloid cells
Bournazos, Stylianos, Wang, Taia T., Ravetch, Jeffrey V. · 2016 · Microbiology Spectrum
Lentinan as an immunotherapeutic for treating lung cancer: a review of 12 years clinical studies in China
Yiran Zhang, Meng Zhang, Yifei Jiang, Xiulian Li, Yanli He, Pengjiao Zeng, Zhihua Guo, Yajing Chang, Heng Luo, Yong Liu et al. · 2018 · Journal of Cancer Research and Clinical Oncology
Impact of linker and conjugation chemistry on antigen binding, Fc receptor binding and thermal stability of model antibody-drug conjugates
Mauro Acchione, Hyewon Kwon, Claudia M. Jochheim, William M. Atkins · 2012 · mAbs
Fc-dependent depletion of activated T cells occurs through CD40L-specific antibody rather than costimulation blockade
Nicola J. Monk, Roseanna E. G. Hargreaves, James Ernest Marsh, Conrad A. Farrar, Steven Howard Sacks, Maggie Millrain, Elizabeth Simpson, Julian Dyson, Stipo Jurčević · 2003 · Nature Medicine
Oncogenic protein tyrosine kinases
Sylvie M�nard, Patrizia Casalini, Manuela Campiglio, Serenella Maria Pupa, Elda Tagliabue · 2004 · Cellular and Molecular Life Sciences
Antagonistic Human FcγRIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo
Ali Roghanian, Ingrid Teige, Linda Mårtensson, Kerry L. Cox, Mathilda Kovacek, Anne Ljungars, Jenny Mattsson, Annika Sundberg, Andrew T. Vaughan, Vallari Shah et al. · 2015 · Cancer Cell
The Evolution of Antibodies into Versatile Tumor-Targeting Agents
Michael Z. Lin, Michael A. Teitell, Gary John Schiller · 2005 · Clinical Cancer Research
Anti-CD20 monoclonal antibodies: reviewing a revolution
Joshua M. L. Casan, Jonathan Wong, Melissa Northcott, Stephen Opat · 2018 · Human Vaccines & Immunotherapeutics
Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity
Xinyue Qi, Fanlin Li, Yi Ming Wu, Cheng Chen, Ping Han, Jieyi Wang, Xuanming Yang · 2019 · Nature Communications
Unleashing Natural Killer Cells in the Tumor Microenvironment–The Next Generation of Immunotherapy?
Aviad Ben‐Shmuel, Guy Biber, Mira Barda‐Saad · 2020 · Frontiers in Immunology
Role of Fcγ receptors in HER2-targeted breast cancer therapy
Antonino Musolino, William John Gradishar, Hope S. Rugo, Jeffrey L. Nordstrom, Edwin P. Rock, Fernanda Irene Arnaldez, Mark Daniel Pegram · 2022 · Journal for ImmunoTherapy of Cancer
Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer
Rupert Bartsch, Andrea Rottenfusser, Catharina Wenzel, Karin Ute Dieckmann, Ursula Pluschnig, Gabriela Altorjai, Margaretha Rudas, Robert M. Mader, Richard Poetter, Christoph Carl Zielinski et al. · 2007 · Journal of Neuro-Oncology
Antibody-mediated rejection: treatment alternatives and outcomes
Neeraj Kumar Singh, John D. Pirsch, Millie Samaniego · 2008 · Transplantation Reviews
Regulated Expression and Inhibitory Function of FcγRIIb in Human Monocytic Cells
Susheela Tridandapani, Kristina Siefker, Jo Ellen Carter, Mark Damian Wewers, Clark L. Anderson, Jean‐Luc Teillaud · 2002 · Journal of Biological Chemistry
Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy
Sherene Loi · 2013 · OncoImmunology
Function and 3D Structure of the N-Glycans on Glycoproteins
Masamichi Nagae, Yoshiki Yamaguchi · 2012 · International Journal of Molecular Sciences
Immunotherapeutic perspective for bispecific antibodies
Annemiek B. van Spriel, Heidi H. van Ojik, Jan G. J. van de Winkel · 2000 · Immunology Today
Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective
John R. Desjarlais, Greg A. Lazar, Eugene A. Zhukovsky, Seung Y. Chu · 2007 · Drug Discovery Today
Multidrug-resistant breast cancer: current perspectives
Darren Charles Tomlinson, Heather L. Martin, Laura Smith · 2014 · Breast Cancer Targets and Therapy
Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy
Jianguang Zhang, Huifang Zheng, Yong Diao · 2019 · International Journal of Molecular Sciences
Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions
David J. DiLillo, Jeffrey V. Ravetch · 2015 · Cancer Immunology Research
Proteolytic Cleavage and Loss of Function of Biologic Agents That Neutralize Tumor Necrosis Factor in the Mucosa of Patients With Inflammatory Bowel Disease
Paolo Biancheri, Randall J. Brezski, Antonio Di Sabatino, Allison R. Greenplate, Keri L. Soring, Gino Roberto Corazza, Klaartje Bel Kok, Laura Rovedatti, Anna Vossenkämper, Nadja Ahmad et al. · 2015 · Gastroenterology
Neutrophils as effector cells for antibody-based immunotherapy of cancer
Marjolein van Egmond, Jantine E. Bakema · 2012 · Seminars in Cancer Biology
Inhibition of Mammalian Target of Rapamycin Is Required for Optimal Antitumor Effect of HER2 Inhibitors against HER2-Overexpressing Cancer Cells
Todd W. Miller, James T. Forbes, Chirayu Shah, Shelby K. Wyatt, H. Charles Manning, Maria Graciela Olivares, Violeta M. Sanchez, Teresa C. Dugger, Nara de Matos Granja, Archana Narasanna et al. · 2009 · Clinical Cancer Research
Alefacept, an Immunomodulatory Recombinant LFA-3/IgG1 Fusion Protein, Induces CD16 Signaling and CD2/CD16-Dependent Apoptosis of CD2+ Cells
Antonio J. da Silva, Margot Brickelmaier, Gerard R. Majeau, Zhifang Li, Lihe Su, Yen‐Ming Hsu, Paula S. Hochman · 2002 · The Journal of Immunology
Complement-Mediated Mechanisms in Anti-GD2 Monoclonal Antibody Therapy of Murine Metastatic Cancer
Masaki Imai, Charles Landen, Rieko Ohta, Nai‐Kong V. Cheung, Stephen Tomlinson · 2005 · Cancer Research
Regulation of Antibody-Dependent Cellular Cytotoxicity by IgG Intrinsic and Apparent Affinity for Target Antigen
Yong Tang, Jianlong Lou, R. Katherine Alpaugh, Matthew K. Robinson, James D. Marks, Louis M. Weiner · 2007 · The Journal of Immunology
Multicenter Phase II Trial of Neoadjuvant Therapy With Trastuzumab, Docetaxel, and Carboplatin for Human Epidermal Growth Factor Receptor-2–Overexpressing Stage II or III Breast Cancer: Results of the GETN(A)-1 Trial
Bruno P. Coudert, Rémy Largillier, Laurent Arnould, Philippe J. M. Chollet, Mario Campone, David Coeffic, Frank Priou, Joseph Gligorov, Xavier Pérez-Martin, Veronique N. Trillet-Lenoir et al. · 2007 · Journal of Clinical Oncology